ArticleNucleic acids research2026
PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining at double-ended DSBs.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interfering with DNA repair pathways to enhance CRISPR-Cas9-mediated homology-directed repair in a chelicerate genetic model.iScience · 2026Article
- Sam68 stimulates polymerase theta-mediated end-joining by suppressing poison exon inclusion in Polq mRNA.Nucleic acids research · 2026Article
- ROS-Induced DNA Damage Enhances Sensitivity to PARP Inhibition in HSC3 and SCC25 Head and Neck Squamous Cell Carcinoma Cell Lines.Current issues in molecular biology · 2026Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Poly ADP-ribose polymerase (PARP) inhibitors are standard of care treatment for cancers with homologous-recombination deficiencies. Yet, as tumours develop resistance, complementary strategies are emerging, including targeting microhomology-mediated end joining (MMEJ). Given that PARP1 is widely described as a key promoter of MMEJ, PARP1 inhibition should suppress MMEJ, making MMEJ inhibition redundant. MMEJ was first characterized as a backup repair pathway, with early studies linking PARP1 to MMEJ in nonhomologous end joining-deficient cells. However, we now recognize that MMEJ is active in cells with intact repair pathways, primarily operating during mitosis. The role of PARP1 in this context remains unclear. Here, we systematically examine how PARP1/2 and PARP inhibition affect MMEJ activity in cells with intact repair pathways. Surprisingly, PARP1/2 inhibition leads to elevated Polθ-dependent MMEJ levels at ISceI-mediated double-stranded DNA breaks (DSBs), an increase that is dependent on homologous recombination. We next show that MMEJ at double-ended DSBs mainly occurs during mitosis, with no detectable activity during G1. Importantly, we show that PARP1 and 2 are dispensable for MMEJ at double-ended DSBs (deDSBs) and is expendable for repair of DSBs during mitosis. Altogether, this data shifts the understanding of the role of PARP1 in MMEJ and DNA repair pathway choice and further strengthens a rationale for PARPi/MMEJi combinatorial drug treatment in HR-deficient cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.